![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | A61K 38/26 | |
A61K 39/395 | |||
A61P 3/10 | |||
C07K 16/24 | |||
A61K 39/00 |
(11) | Number of the document | 3139948 |
(13) | Kind of document | T |
(96) | European patent application number | 15720982.6 |
Date of filing the European patent application | 2015-05-05 | |
(97) | Date of publication of the European application | 2017-03-15 |
(45) | Date of publication and mention of the grant of the patent | 2020-03-04 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/EP2015/059811 |
Date | 2015-05-05 |
(87) | Number | WO 2015/169789 |
Date | 2015-11-12 |
(30) | Number | Date | Country code |
201461989841 P | 2014-05-07 | US | |
14169596 | 2014-05-23 | EP | |
14189732 | 2014-10-21 | EP |
(72) |
COPPIETERS, Ken, DK
VON HERRATH, Matthias, US
BOURSALIAN, Tamar, US
|
(73) |
Novo Nordisk A/S,
Novo Allé, 2880 Bagsvęrd,
DK
|
(54) | TREATMENT OF DIABETES TYPE 1 USING GLP-1 AND ANTI-IL-21 |
TREATMENT OF DIABETES TYPE 1 USING GLP-1 AND ANTI-IL-21 |